Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIJNLG)

Drug Name
Semapimod Drug Info
Synonyms CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
Inflammatory bowel disease DD72 Phase 2 [1]
Cross-matching ID
PubChem CID
5745214
CAS Number
CAS 352513-83-8
TTD Drug ID
DMIJNLG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proto-oncogene c-RAF (c-RAF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BGB-3245 DM1X3L0 Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
GDC-5573 DMJA27W Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Belvarafenib DM0ZNAR Solid tumour/cancer 2A00-2F9Z Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-RAF (c-RAF) TTB18GJ RAF1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00038766) CNI-1493 for Treatment of Moderate to Severe Crohn's Disease. U.S. National Institutes of Health.
2 Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
3 Clinical pipeline report, company report or official report of BeiGene.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.